RSS Feeds
Search

Industry news

Orphagen Pharmaceuticals Awarded Phase 2 SBIR Funding to Investigate Novel Drug Class for CNS Disorders

In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.

Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.

Subscribe now for instant access to the benefits Pharmalicensing Intelligence has to offer. Find out more.

Company details

If you want to find out more about the company visit Orphagen Pharmaceuticals profile.

Related reports

Market Research Reports provided by reports.iptechex.com
The CNS Pipeline Fact Book 2012
Feb 2012 - 70 pages - $690
The CNS Market Outlook to 2016
Jul 2011 - 170 pages - $3,835
CNS Drug Discoveries: Depression Chapter
Aug 2008 - 88 pages - $1,040
CNS Drug Discoveries: Schizophrenia Chapter
Aug 2008 - 84 pages - $1,040
CNS Generic Drugs: Prospects and Opportunities to 2012
Apr 2008 - 290 pages - $1,740
CNS Drug Discoveries: Alzheimer's Disease Chapter
Aug 2008 - 62 pages - $1,040
CNS Drug Discoveries: Multiple Sclerosis Chapter
Aug 2008 - 128 pages - $1,040
CNS Drug Discoveries: Parkinson's Disease Chapter
Aug 2008 - 74 pages - $1,040
Myeloproliferative Disorders-Research Consortium – Developmental Therapeutics Review – Q4 2010
Dec 2010 - 22 pages - $500
CNS Market Trends, 2007 to 2010 : Key Market Forecasts and Growth Opportunities
Jun 2007 - 125 pages - $2,010
More Related Market Research Reports >>>

Related news

Latest News

Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression
Orphagen Pharmaceuticals Awarded Phase 2 SBIR Funding to Investigate Novel Drug Class for CNS Disorders
More news... | RSS Feed...

Most Viewed

Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression

Orphagen Pharmaceuticals Awarded Phase 2 SBIR Funding to Investigate Novel Drug Class for CNS Disorders

Therapeutic Target

Cardiovascular
Dermatology
Endocrine and Metabolic
Gastroenterology
Genitourinary
Hematology
Immunology and Allergy
Infection
Musculoskeletal
Neurology
Obstetrics and Gynecology
Oncology
Ophthalmology
Psychiatry
Pulmonary

Categories

Deals and Alliances
Development
Financial Results
Financings
Intellectual Property
Regulatory
Press releases
Deals review
Headlines
PR Newswire

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us